Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Parexel FSP provides biopharmaceutical customers the full spectrum of outsourcing solutions from full service to functional to a hybrid approach across a range of specialized disciplines...
Cloud Platform Built on Microsoft Azure Delivers PAREXEL’s Valued Informatics Solutions on a Global, Trusted Architecture; Represents the First Offering of PAREXEL and Microsoft Alliance...
New Appointments Enhance PAREXEL’s Leadership and Expertise in Bringing Commercially Viable, Reimbursable Products to Market PAREXEL, a leading global biopharmaceutical services provider...
PAREXEL International Corporation (NASDAQ: PRXL) ("PAREXEL" or the "Company"), a leading global biopharmaceutical services company, announced that Pamplona Capital Management, LLP...
Six Flags Entertainment and Sterling Bancorp Set to Join S&P MidCap 400; Oil States Intl. and KEMET to Join S&P SmallCap 600 PR Newswire NEW YORK, Sept. 26, 2017 NEW YORK, Sept. 26, 2017...
PAREXEL International Corporation (NASDAQ: PRXL) ("PAREXEL" or the "Company"), a leading global biopharmaceutical services company, announced today that its shareholders, at a special...
Integrated offering to be provided by new dedicated service group under PAREXEL® Access PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services...
Fourth-quarter 2017 service revenue of $557.2 million Fourth-quarter 2017 GAAP diluted EPS of $0.58; adjusted diluted EPS of $1.02 Full-year 2017 service revenue of $2,117.6...
PAREXEL International Corporation (NASDAQ: PRXL) will release financial results for the Fourth Quarter and Fiscal Year 2017 on Monday, August 28, 2017, after the close of the stock market...
Alliance to drive greater efficiencies across clinical trials in oncology and hematology PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
